Cathay Capital has led a EUR30 million ($33 million) round of funding for Echosens, a France-based diagnostic medical device manufacturer owned by China’s Inner Mongolia FuRui Medical Science.
Yunfeng Capital, Shenzhen Cowin Capital, New Horizon Capital and Hunan Haijie Healthcare Investment have provided RMB200 million ($32 million) in Series B funding for Huakang Mobile Healthcare, a Chinese mobile healthcare app developer.
China Cord Blood, a US-listed blood banking operator in which KKR holds a minority stake, has received a take-private offer from its largest shareholder, Chinese healthcare company Golden Meditech.
With A$78 billion ($61 billion) in assets, AustralianSuper is said to struggle to make fund commitments of less than A$150 million. Yet it is one of several superannuation funds backing Brandon Capital’s latest life sciences VC vehicle, which has closed...
China's Fosun International and Tencent Holdings have led a $35 million Series B round for Scanadu, a US-based medical technology start-up working on devices that can send diagnostic tests directly to smart phones.
DocDoc, the Singapore-based start-up behind the Asian doctor discovery platform of the same name, has raised a Series A round worth S$11.5 million ($8.5 million) from US and Korea-based SparkLabs Global Ventures, and Malaysian conglomerate Hong Leong...
Indian biopharmaceutical firm Biocon has filed for an IPO for its research arm Syngene International, which is backed by India Value Fund Advisors (IVFA).
Laobaixing Pharmacy Chain (LBX Pharmacy), a Chinese retail pharmacy chain backed by EQT Partners, closed up 44% on its price on the first day of trading in Shanghai.
GIC Private, China Renaissance Capital Investment (CRCI) and GL Capital Group are among 26 investors subscribing to a HK$5 billion ($645 million) share placement by China Traditional Chinese Medicine (China TCM), intended to generate capital for acquisitions.
Australian life sciences-focused VC firm Brandon Capital has reached a A$200 million ($154 million) final close on its latest vehicle - the Medical Research Commercialisation Fund 3 (MRCF 3).
Singapore state-backed investment group Temasek Holdings has invested INR9.45 billion ($151 million) in India's Glenmark Pharma via a preferential allotment of shares.
Hony Capital has sold HK$9.78 billion ($1.26 billion) worth of shares in CSPC Pharmaceutical to complete its exit from the Hong Kong-listed Chinese drug manufacturer.
Alibaba Group plans to inject the operations of its online pharmacy business into Alibaba Health Information Technology (Alibaba Health), a Hong Kong-listed healthcare company that it bought alongside Yungfeng Capital last year, in a deal worth HK$19.4...
TVM Capital Life Science has reached a first close of $50 million on its debut China fund, which will invest in Western companies with a view to obtaining licenses for development and commercialization in China.
Warburg Pincus has exited its entire 27% stake in Indian healthcare chain Metropolis to the Shah family, one of the company's promoters. KKR backed the Shah family's buyback.
Johnson & Johnson Innovation (JJDC) - the venture capital arm of the eponymous healthcare and consumer goods multinational - has committed to $15 million to Vivo Capital's latest US and China-focused healthcare fund.
Meinian Onehealth Healthcare Group, the largest private provider of preventive healthcare check-up services in China and a portfolio company of The Carlyle Group among others, plans to list in Shenzhen through a reverse merger with Jiangsu Sanyou Group.
Healthcare-focused Vivo Capital has attracted increasing attention from LPs for its hybrid focus on the US and China. As testament to this, its latest fund - Vivo Capital Fund VIII - closed at $750 million after nine months in the market, with demand...
Megakaryon, a Japan-based stem cell technology developer, has raised JPY2.54 billion ($21.2 million) from a consortium of investors including existing backers Innovation Network Corporation of Japan (INCJ), Mitsubishi UFJ Capital, SMBC Venture Capital...
US-based Vivo Capital has closed its eighth fund at $750 million. It will invest in healthcare companies in the US and China.
Hong Kong-based seed investor Nest has appointed Peter Dingle, formerly of Intel Corporation, to lead its newly-established Branded Accelerators program.
Indonesia’s middle market is a proxy for the robust services sector, but it is difficult for investors to penetrate and deal flow has been slow in recent years. Are we are about to see more?
IDG Capital Partners and South Korea's Small and Medium Business Administration have agreed to form a KRW100 billion ($91 million) VC fund that will help Korean businesses enter the China market.
International Finance Corporation (IFC) has invested $5.5 million in Indian eye clinic chain Eye-Q Vision, leading a round of financing for the company worth $10 million.